De Novo device
LIAISON® XL MUREX Anti-HDV (318260)
DiaSorin, Inc. · Device To Detect Antibodies To Hepatitis D Virus (SGW, Class II) · First FDA decision Dec 23, 2025, newest Dec 23, 2025HIV, hepatitis and sexually transmitted infectionsLiver disease and liver cancer
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
1
Naming "LIAISON XL MUREX"
MAUDE reports
1
Brand "LIAISON XL MUREX", since 2015
PubMed studies
22
Mentioning "LIAISON XL MUREX"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- LIAISON® XL MUREX Anti-HDV (318260); LIAISON® XL MUREX Control Anti-HDV (318261)New device typeBreakthroughDe Novo
DEN250032 · Decided Dec 23, 2025 · 146 days after receipt
Device type: Device To Detect Antibodies To Hepatitis D Virus (SGW) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Screening for Hepatitis C Virus (HCV) in AdultsNational analysisUnder reviewCAG-00436RUpdated Sep 23, 2026
- Screening for Hepatitis C Virus (HCV) in AdultsNational analysisReview closedCAG-00436NUpdated Sep 22, 2026
- Screening for Hepatitis B Virus (HBV) InfectionNational analysisReview closedCAG-00447NUpdated Sep 22, 2026
- Screening for Hepatitis C Virus (HCV) in AdultsNational determinationOn the books210.13Updated Apr 7, 2026
- Screening for Hepatitis B Virus (HBV) InfectionNational determinationOn the books210.6Updated Dec 2, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "LIAISON XL MUREX", any status and sponsor, newest update first.
bioLytical LaboratoriesNot on our public-company list
NCT06368466 · 175 participants · Start Apr 30, 2024 · Primary completion Jul 5, 2024
Device: iStatis HBsAg Test · For: Hepatitis B; Hepatitis B Infection
Sites: Melbourne, Australia
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "LIAISON XL MUREX", and for the whole product code for context.
This brand
1 reports: 1 malfunction, 0 injury, 0 death
Whole product code SGW
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
- LIAISON XL MUREX HCV ABMalfunction
2182595-2020-00001 · Received Nov 27, 2020 · Event dated Oct 29, 2020
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO)
Device problem as coded: No Apparent Adverse Event
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "LIAISON XL MUREX"[tiab]. The summary above synthesizes these.
- Assessment of Liaison XL Murex Chagas diagnostic performance in blood screening for Chagas disease using a reference array of chimeric antigens.
Santos EF, Leony LM, Silva ÂAO, et al. · Transfusion · 2021Research Support, Non-U.S. Gov't
- Performance of the Liaison® XL Murex recHTLV-I/II Immunoassay in the Detection of HTLV-1/2 Antibodies in Serum.
Gantner P, Velay A, Guigue N, et al. · Clin Lab · 2017
- Superior Performance of Newly Developed Alinity Anti-HCV Next Assay in the Diagnosis of HCV Infection.
Ponnuvel S, Ali H, Prakash A, et al. · J Med Virol · 2025Evaluation Study, Research Support, Non-U.S. Gov't
- Comparison of two new HTLV-I/II screening methods, Abbott Alinity i rHTLV-I/II and Diasorin LIAISON® XL murex recHTLV-I/II, to Abbott architect rHTLVI/II assay.
Guiraud V, Crémoux F, Leroy I, et al. · J Clin Virol · 2023
- Performance of the Liaison XL Murex HIV Ab/Ag test on clinical samples representing current epidemic HIV variants.
Lemee V, Leoz M, Etienne M, et al. · J Clin Microbiol · 2014Comparative Study, Evaluation Study
- Clinical performance of the novel DiaSorin LIAISON(®) XL murex: HBsAg Quant, HCV-Ab, HIV-Ab/Ag assays.
Krawczyk A, Hintze C, Ackermann J, et al. · J Clin Virol · 2014Comparative Study, Evaluation Study
- Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: correlation with the ARCHITECT quantitative assays.
Burdino E, Ruggiero T, Proietti A, et al. · J Clin Virol · 2014Comparative Study
- Validation study of an automated chemiluminiscence assay to detect HIV antibodies in oral fluid specimens.
González V, López N, Grifols J, et al. · Eur J Clin Microbiol Infect Dis · 2022
- Evaluation of the Vitros® Anti-T. cruzi assay for its incorporation into the Trypanosoma cruzi infection diagnostic algorithm.
Campos-Ruiz M, Wang-Wang JH, Rivaya B, et al. · Heliyon · 2024
- Comparison of anti-hepatitis D virus (HDV) ETI-AB-DELTAK-2 assay and the novel LIAISON® XL MUREX anti-HDV assay in the diagnosis of HDV infection.
Rocco C, Bonavolta R, Vallefuoco L, et al. · Diagn Microbiol Infect Dis · 2019Comparative Study
- Combined HDV RNA and anti-HDV measurement for the management of HBV/HDV coinfection.
Ricco G, Cavallone D, Colombatto P, et al. · Hepatology · 2026
- Molecular and genetic characterization of hepatitis B virus among multitransfused thalassaemia patients in Islamabad, Pakistan.
Farooq A, Waheed U, Saba N, et al. · J Family Med Prim Care · 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.